# US 2021/0275580 A1 · Iron carbohydrate complex for treatment of restless leg syndrome (rls)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275580 A1
- Document ID: US20210275580A1
- Status: Published application
- Kind: A1
- Application number: 17/182,366
- Filed: 2021-02-23
- Published: 2021-09-09
- Earliest claimed: 2015-03-19
- Assignees: Pharmacosmos Holding A/S
- Applicants: Pharmacosmos Holding A/S
- Inventors: Lars Lykke THOMSEN; Tobias S. CHRISTENSEN; Hans ANDREASEN
- Web page: https://patentgrep.com/patent/US20210275580A1

## CPC

- A61K 33/26: Iron; Compounds thereof
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, wherein the human patient prior to treatment has a magnetic resonance phase imaging of 0.02 radians above the average value of a control group in the substantia nigra, thalamus, putamen, orpallidum. The invention provides a higher probability for a RLS patient being treated to experience a relief in symptoms.

## Claims

### Claim at position 1

-40. (canceled)

### Claim 41

A method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, comprising:
(a) identifying a patient having an elevated magnetic resonance phase imaging of 0.04 radians above the normal value in the substantia nigra, thalamus, putamen, or pallidum; and
(b) administering to the patient an effective amount of a pharmaceutical composition comprising an iron carbohydrate complex;
wherein the iron carbohydrate complex comprises an iron reduced glucooligosaccharide; and
wherein the weight average molecular weight (MW) of the carbohydrate component of the iron carbohydrate complex is 800 to 2,000 Dalton.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the weight average molecular weight of the carbohydrate component is around 1,000 Dalton.

### Claim 43 (depends on 41)

The method according to claim 41, wherein the apparent molecular weight of the iron carbohydrate complex measured relative to dextran standards is 200,000 Daltons or less.

### Claim 44 (depends on 41)

The method according to claim 41, wherein the pharmacokinetic half-life (t1/2) of the iron carbohydrate complex is 10 hours or more, 12 hours or more, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, or more.

### Claim 45 (depends on 44)

The method according to claim 44, wherein the pharmacokinetic half-life (t1/2) of the iron carbohydrate complex is 20 hours or more, or is 22 hours or more.

### Claim 46 (depends on 41)

The method according to claim 41, wherein the iron carbohydrate complex comprises a carbohydrate component comprising a backbone of glucose units linked by α-1,6 glycosidic linkages and optionally branches of glucose units linked to the backbone through α-1,3 glycosidic linkages, wherein the proportion of α-1,3 glycosidic linkages to α-1,6 glycosidic linkages is less than 2:100, or is less than 1:100.

### Claim 47 (depends on 41)

The method according to claim 41, wherein the carbohydrate component does not comprise detectable branches of glucose units linked by a α-1,3 glycosidic linkages to the backbone.

### Claim 48 (depends on 41)

The method according to claim 41, wherein the iron carbohydrate complex comprises (1→6)-α-D-glucopyranan-(1→6)-D-glucitol iron(III) complex.

### Claim 49 (depends on 41)

The method according to claim 41, wherein the pharmacokinetic half-life (t1/2) of the iron carbohydrate complex is 20 hours or more,
the iron carbohydrate complex comprises (1→6)-α-D-glucopyranan-(1→6)-D-glucitol iron(III) complex,
the weight average molecular weight (MW) of the carbohydrate component of the iron carbohydrate complex is around 1,000 Dalton, and
the apparent molecular weight of the iron carbohydrate complex measured relative to dextran standards is 200,000 Dalton or less.

### Claim 50 (depends on 41)

The method according to claim 41, wherein the iron carbohydrate complex is iron isomaltoside 1000.

### Claim 51 (depends on 41)

The method according to claim 41, wherein the total dose of elemental iron from the iron carbohydrate complex administered to the RLS patient is 300 mg elemental iron or more, 400 mg elemental iron or more, 500 mg elemental iron, 600 mg elemental iron, 700 mg elemental iron, 800 mg elemental iron, 900 mg elemental iron, or more.

### Claim 52 (depends on 41)

The method according to claim 41, wherein the total dose of elemental iron from the iron carbohydrate complex administered to the RLS patient is 800 mg elemental iron or more, 900 mg elemental iron or more, or is 1,000 mg elemental iron.

### Claim 53 (depends on 41)

The method according to claim 41, wherein the pharmaceutical composition is a liquid formulation suitable for parenteral injection or infusion, optionally after appropriately being diluted.

### Claim 54 (depends on 41)

The method according to claim 41, wherein the pharmaceutical composition is infused into a patient during a 3 to 30 minute time period, or a 5 to 25 minute time period.

### Claim 55 (depends on 41)

The method according to claim 41, wherein the iron carbohydrate complex is iron isomaltoside 1000, the total dose of elemental iron from the iron carbohydrate complex administered to the RLS patient is 800 mg elemental iron or more, and the pharmaceutical composition is infused into the patient during a 3 to 30 minute time period; in particular wherein the iron carbohydrate complex is iron isomaltoside 1000, the total dose of elemental iron from the iron carbohydrate complex administered to the RLS patient is 1,000 mg elemental iron, and the pharmaceutical composition is administered as a single dose which is infused into the patient during a 3 to 30 minute time period.

### Claim 56 (depends on 41)

The method according to claim 41, wherein the patient is subjected to a further administration of the iron carbohydrate complex if one or more of the symptoms of RLS recurs.

### Claim 57 (depends on 56)

The method according to claim 56, wherein the further administration is performed 1 month to 12 months after the previous administration.

### Claim 58 (depends on 41)

The method according to claim 41, wherein the normal value is a magnetic resonance phase imaging value of:
Substantia nigra: −0.103
Thalamus: −0.069
Putamen: −0.146
Pallidum: −0.182.

### Claim 59

A method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, comprising:
(a) identifying a patient having an elevated magnetic resonance phase imaging of 0.04 radians above the normal value in the substantia nigra, thalamus, putamen, or pallidum; and
(b) administering to the patient an effective amount of a pharmaceutical composition comprising an iron carbohydrate complex;
wherein the iron carbohydrate complex is iron isomaltoside 1000.

### Claim 60

A method for treatment or prevention of Restless Leg Syndrome (RLS) of a human patient, comprising:
(a) identifying a patient having an elevated magnetic resonance phase imaging of 0.04 radians above the normal value in the substantia nigra, thalamus, putamen, or pallidum; and
(b) administering to the patient an effective amount of a pharmaceutical composition comprising an iron carbohydrate complex;
wherein the iron carbohydrate complex is iron isomaltoside 1000;
wherein the total dose of elemental iron from the iron carbohydrate complex administered to the RLS patient is 800 mg elemental iron or more, or is 1,000 mg elemental iron; and
wherein the pharmaceutical composition is infused into the patient during a 3 to 30 minute time period.
